Multi-Institution Chinese Research Team Finds SOX30 Methylation Correlates with Disease Progression

Jun 21, 2019 | China, Chronic Myeloid Leukemia, CML, SOX30 Methylation

Multi-Institution Chinese Research Team

A large multi-university Chinese research team previously reported aberrant SOX30 methylation was associated with poor prognosis in AML, and it correlates with disease progression in MDS. The Chinese team further determined SOX30 methylation and its clinical significance in the other myeloid malignance—chronic myeloid leukemia (CML).

The Study

SOX30 methylation was examined in real-time quantitative methylation-specific PCR and bisulfite sequencing PCR, whereas SOX30 expression was detected by real-time quantitative PCR.


SOX30 methylation was identified in 11% CML patients. SOX30 methylation was associated with lower hemoglobin and platelets (P=0.006 and 0.032, respectively). Importantly, significant differences were observed in the distributions of clinical stages and cytogenetics (P=0.006 and 0.002, respectively). The frequency of SOX30 methylation in chronic phase (CP) stage occurred with lowest frequency (4/74, 5%), higher in accelerated phase (AP) stage (1/7, 14%), and the highest in blast crisis (BC) stage (12/31, 39%). In addition, SOX30 methylated patients tended to have a higher level of BCR-ABL transcript than SOX30 non-methylated patients (P=0.063). In two paired CML patients, SOX30 methylation showed lower density in CP stage (19% and 17%, respectively), and was significantly increased in BC stage (89% and 69%, respectively) during disease progression. Additionally, SOX30 methylated CML patients presented a lower SOX30 transcript level than SOX30 non-methylated CML patients (P=0.046).


The Chinese study reveals that SOX30 methylation is correlated with disease progression in chronic myeloid leukemia.

Research Institutions

  • Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China
  • Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, People’s Republic of China
  • The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China
  • Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China


Pin It on Pinterest